Accelerated partial breast irradiation inequivalent to whole breast irradiation for ipsilateral breast tumor recurrence

December 6, 2018, American Association for Cancer Research
Credit: CC0 Public Domain

Data from the NRG (NSABP B-39/RTOG 0413) trial indicated that ipsilateral breast tumor recurrence (IBTR) rates 10 years after treatment could not reject the hypothesis that accelerated partial breast irradiation (PBI) after lumpectomy was inferior to whole breast irradiation (WBI), according to a presentation at the 2018 San Antonio Breast Cancer Symposium, held Dec. 4–8.

Moreover, the 10-year estimates for relapse-free interval (RFI) disclosed a statistically significant inferiority for PBI compared to WBI. Because the differences relative to both IBTR and RFI were small, PBI may be an acceptable alternative to WBI for a proportion of women who undergo breast-conserving surgery.

"Because of advancements in screening and public awareness, the majority of in the U.S. are diagnosed in early stages, and over 100,000 women each year face decisions about breast-conserving therapy," said Frank Vicini, MD, principal investigator at the MHP Radiation Oncology Institute/21st Century Oncology in Pontiac, Michigan. "It is important that breast and the health care system have modern information about breast-conservation treatment and options that can improve access to care, combat overtreatment, reduce the burden of treatment and health care costs, and improve quality of life."

WBI following lumpectomy has comparable ipsilateral recurrence rates compared to mastectomy, Vicini explained. Accelerated PBI treats the tumor bed area instead of the entire breast and reduces radiation treatment time from 3-6 weeks to 5-8 days, he noted. "The main purpose of our study was to determine if accelerated PBI is equivalent to WBI in controlling for ipsilateral breast cancer recurrence in women who desire breast-conservation surgery," he said.

Vicini, Julia White, MD, co-principal investigator at The Ohio State University, and colleagues randomized breast cancer patients who had recently received a lumpectomy with 0-3 positive axillary nodes to treatment with WBI or PBI. Of these breast cancer patients, 25 percent had ductal carcinoma in situ (DCIS), 65 percent had stage I breast cancer, and 10 percent had stage II breast cancer. Eighty-one percent of patients had hormone receptor-positive cancer, and 61 percent of patients were postmenopausal.

Of the 4,216 breast cancer patients, 2,109 received WBI and 2,107 received PBI. Treatment with WBI was defined as daily treatment with 2 grays (Gy) of radiation totaling 50 Gy with a sequential boost to the surgical site; treatment with PBI was defined as twice daily treatment with 3.4-3.85 Gy totaling 10 treatments delivered via 3-D external beam radiation or brachytherapy.

The primary endpoint of the trial was evidence of IBTR. Secondary endpoints included RFI, distant disease-free interval (DDFI), and overall survival (OS). The median follow-up time was 10.2 years. Disease-free survival (DFS) was also analyzed.

IBTR as a first event was observed in 161 women; of these patients, 90 had received PBI, while 71 had received WBI. While the risk of recurrence was not statistically different between the two treatment arms, the hazard ratio did not meet the statistical criteria for treatment equivalence, Vicini explained.

The proportion of patients IBTR-free 10 years after treatment was 95.2 percent among those who received PBI and 95.9 percent among those who received WBI. The difference in the 10-year RFI between the two treatment arms was statistically significant (91.9 percent for patients treated with PBI versus 93.4 percent for patients treated with WBI).

"Despite only small differences in IBTR (<1 percent) and RFI (1.5 percent) between the two treatment arms at 10 years, we could not declare that WBI and PBI were equivalent in controlling local in- tumor recurrence because the hazard ratio between arms fell short of meeting statistical equivalence," said Vicini "On the other hand, we also could not claim that it is inferior."

Importantly, statistically significant differences between the two treatment arms were not observed for DDFI, DFS, or OS, noted Vicini. "These findings suggest that the less burdensome radiation method of accelerated PBI may be an acceptable choice for many women," said Vicini. "Additional analyses are underway to determine if specific cohorts may have advantages in local and regional relapse control between the two treatment arms."

Grade 3 toxicity was modestly higher in patients who received PBI compared to those who received WBI (9.6 percent and 7.1 percent, respectively). Likewise, grade 4-5 toxicity was slightly higher in patients who received PBI compared to those who received WBI (0.5 percent and 0.3 percent, respectively).

"The delivery of radiation is operator-dependent and it will be important to complete future analyses to determine the influence on radiation quality and technical treatment delivery on toxicity outcomes," Vicini said.

While multiple methods of PBI were utilized in the trial, a limitation of the study was a lack of statistical power to determine which PBI technique is optimal in individual clinical scenarios, noted Vicini.

Explore further: Lumpectomy + radiation may cut breast cancer mortality in DCIS

Related Stories

Lumpectomy + radiation may cut breast cancer mortality in DCIS

August 20, 2018
(HealthDay)—Treatment with lumpectomy and radiotherapy is associated with a reduction in breast cancer mortality versus lumpectomy or mastectomy alone among patients with ductal carcinoma in situ (DCIS), according to a ...

Avoiding radiotherapy is an option for some older patients with breast cancer

December 11, 2013
Omission of radiotherapy is a reasonable option for women age 65 or older who receive hormone therapy after breast-conserving surgery for hormone receptor-positive, axillary node-negative breast cancer, according to results ...

Outcomes similar with partial, whole breast irradiation

August 24, 2012
(HealthDay)—Accelerated partial breast irradiation (APBI) yields five-year clinical outcomes and patterns of failure similar to those achieved with whole breast irradiation (WBI), with excellent three-year survival for ...

Potential new surgical options for women with multiple ipsilateral breast cancer

July 12, 2018
A new multi-institutional clinical trial compared outcomes of women with multiple ipsilateral breast cancer, or more than one site of disease in the same breast, who underwent breast-conserving surgery, with outcomes of those ...

Radiation boost reduces local tumor recurrence for DCIS patients following WBRT

September 27, 2016
A supplemental "boost" of radiation improves local control and provides an incremental benefit in decreasing breast cancer recurrence for patients with Ductal Carcinoma In Situ (DCIS) who receive whole breast radiation therapy ...

Recommended for you

Immunotherapy combo not approved for advanced kidney cancer patients on the NHS

December 14, 2018
People with a certain type of advanced kidney cancer will not be able to have a combination of two immunotherapy drugs on the NHS in England.

New drug seeks receptors in sarcoma cells, attacks tumors in animal trials

December 13, 2018
A new compound that targets a receptor within sarcoma cancer cells shrank tumors and hampered their ability to spread in mice and pigs, a study from researchers at the University of Illinois reports.

Surgery unnecessary for many prostate cancer patients

December 13, 2018
Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian ...

Combining three treatment strategies may significantly improve melanoma treatment

December 12, 2018
A study by a team led by a Massachusetts General Hospital (MGH) investigator finds evidence that combining three advanced treatment strategies for malignant melanoma—molecular targeted therapy, immune checkpoint blockade ...

Researchers use computer model to predict prostate cancer progression

December 12, 2018
An international team of cancer researchers from Denmark and Germany have used cancer patient data to develop a computer model that can predict the progression of prostate cancer. The model is currently being implemented ...

New insight into stem cell behaviour highlights therapeutic target for cancer treatment

December 12, 2018
Research led by the University of Plymouth and Technische Universität Dresden has identified a new therapeutic target for cancer treatment and tissue regeneration – a protein called Prominin-1.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.